• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.

作者信息

Sanchez-Pernaute Olga, Romero-Bueno Fredeswinda I, Selva-O'Callaghan Albert

机构信息

Rheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.

Rheumatology Division, Jiménez Díaz Foundation University Hospital and Health Research Institute, Universidad Autónoma de Madrid, Madrid, Spain.

出版信息

Reumatol Clin (Engl Ed). 2021 Nov;17(9):556-557. doi: 10.1016/j.reumae.2020.03.005.

DOI:10.1016/j.reumae.2020.03.005
PMID:34756322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8555974/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0653/8555974/4ef191d79165/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0653/8555974/4ef191d79165/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0653/8555974/4ef191d79165/gr1_lrg.jpg

相似文献

1
Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia.为何选择环孢素A作为新冠肺炎的一线治疗药物。
Reumatol Clin (Engl Ed). 2021 Nov;17(9):556-557. doi: 10.1016/j.reumae.2020.03.005.
2
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation.接受糖皮质激素联合或不联合托珠单抗治疗COVID-19相关过度炎症的患者对SARS-CoV-2的抗体反应。
Ann Rheum Dis. 2021 Oct;80(10):1362-1363. doi: 10.1136/annrheumdis-2021-220040. Epub 2021 May 6.
3
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.视神经脊髓炎谱系障碍患者在新冠疫情期间的免疫抑制：一项新挑战。
Mult Scler Relat Disord. 2020 Jun;41:102097. doi: 10.1016/j.msard.2020.102097. Epub 2020 Apr 5.
4
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.白细胞介素-6阻断治疗用于一名慢性髓性白血病控制不佳患者的新型冠状病毒肺炎相关细胞因子释放综合征
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.
5
Is IL-6 a key cytokine target for therapy in COVID-19?白细胞介素-6 是 COVID-19 治疗的关键细胞因子靶点吗？
Nat Rev Immunol. 2021 Jun;21(6):337-339. doi: 10.1038/s41577-021-00553-8.
6
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
7
COVID-19: Some clinical questions after the first 4 months.新冠病毒病（COVID-19）：最初4个月后的一些临床问题
Eur J Clin Invest. 2020 Jul;50(7):e13326. doi: 10.1111/eci.13326. Epub 2020 Jul 5.
8
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
9
COVID-19-induced hyperinflammation, immunosuppression, recovery and survival: how causal inference may help draw robust conclusions.COVID-19 引起的过度炎症、免疫抑制、恢复和存活：因果推断如何帮助得出可靠的结论。
RMD Open. 2021 Mar;7(1). doi: 10.1136/rmdopen-2021-001638.
10
Cytokines and COVID-19: friends or foes?细胞因子与 COVID-19：是敌是友？
Hum Vaccin Immunother. 2020 Oct 2;16(10):2363-2365. doi: 10.1080/21645515.2020.1799669. Epub 2020 Aug 25.

引用本文的文献

1
Critical illness in immunocompromised patients: insights into relapse or persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): case series report.免疫功能低下患者的危重症：对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）复发或持续感染的见解：病例系列报告
J Med Case Rep. 2025 Jul 27;19(1):371. doi: 10.1186/s13256-025-05431-8.
2
Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial.环孢素A作为COVID-19患者基于皮质类固醇的背景治疗的附加疗法：一项多中心随机临床试验。
J Clin Med. 2024 Sep 4;13(17):5242. doi: 10.3390/jcm13175242.
3

本文引用的文献

1
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
2
Intracellular sensing of viral genomes and viral evasion.病毒基因组的细胞内感应和病毒的逃逸。
Exp Mol Med. 2019 Dec 11;51(12):1-13. doi: 10.1038/s12276-019-0299-y.
3
Mitochondria in innate immune signaling.线粒体在先天免疫信号中的作用。
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.
COVID-19 中巨噬细胞活化综合征有吸引力的治疗方法进展。
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
4
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.新冠病毒感染中的炎症通路：机制与治疗干预措施
MedComm (2020). 2022 Aug 1;3(3):e154. doi: 10.1002/mco2.154. eCollection 2022 Sep.
5
Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.环孢素 A 通过三种 SARS-CoV-2 变体抑制肺细胞中的病毒感染和释放以及细胞因子产生。
Microbiol Spectr. 2022 Feb 23;10(1):e0150421. doi: 10.1128/spectrum.01504-21. Epub 2022 Jan 5.
Transl Res. 2018 Dec;202:52-68. doi: 10.1016/j.trsl.2018.07.014. Epub 2018 Aug 7.
4
A Novel In Vitro CypD-Mediated p53 Aggregation Assay Suggests a Model for Mitochondrial Permeability Transition by Chaperone Systems.一种新型的体外CypD介导的p53聚集测定法提示了伴侣系统介导线粒体通透性转换的模型。
J Mol Biol. 2016 Oct 9;428(20):4154-4167. doi: 10.1016/j.jmb.2016.08.001. Epub 2016 Aug 8.
5
Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.早期环孢素治疗皮肌炎相关间质性肺病的生存获益。
Rheumatol Int. 2016 Jan;36(1):125-31. doi: 10.1007/s00296-015-3328-8. Epub 2015 Jul 30.
6
The mitochondrial unfolded protein response, a conserved stress response pathway with implications in health and disease.线粒体未折叠蛋白反应，一种保守的应激反应途径，与健康和疾病有关。
J Exp Biol. 2014 Jan 1;217(Pt 1):137-43. doi: 10.1242/jeb.090738.
7
MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.中东呼吸综合征冠状病毒复制可诱导严重的体外细胞病变，环孢素 A 或干扰素-α 处理可强烈抑制其复制。
J Gen Virol. 2013 Aug;94(Pt 8):1749-1760. doi: 10.1099/vir.0.052910-0. Epub 2013 Apr 25.
8
The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors.严重急性呼吸综合征冠状病毒-宿主相互作用组：亲环素作为泛冠状病毒抑制剂的靶标鉴定。
PLoS Pathog. 2011 Oct;7(10):e1002331. doi: 10.1371/journal.ppat.1002331. Epub 2011 Oct 27.
9
Suppression of NF-kappaB by cyclosporin a and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response.环孢素A和他克莫司（FK506）通过诱导C/EBP家族抑制核因子κB：对未折叠蛋白反应的影响
J Immunol. 2009 Jun 1;182(11):7201-11. doi: 10.4049/jimmunol.0801772.
10
Effect of cyclosporine on reperfusion injury in acute myocardial infarction.环孢素对急性心肌梗死再灌注损伤的影响。
N Engl J Med. 2008 Jul 31;359(5):473-81. doi: 10.1056/NEJMoa071142.